Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis

European Journal of Pharmacology

Volumn 615, Issue 1-3, 2009, Pages 113-117

  Mashiko, Satoshi ^a   Moriya, Ryuichi ^a   Ishihara, Akane ^a   Gomori, Akira ^a   Matsushita, Hiroko ^a   Egashira, Shinichiro ^a   Iwaasa, Hisashi ^a   Takahashi, Toshiyuki ^a   Haga, Yuji ^a   Fukami, Takehiro ^a   Kanatani, Akio ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Energy homeostasis; Neuropeptide Y; Y1 receptor; Y5 receptor

Indexed keywords

2 [1 (3 CHLORO 5 ISOPROPYLOXYCARBONYLAMINOPHENYL)ETHYLAMINO] 6 [2 (ETHYL 4 METHYL 1,3 THIAZOL 2 YL)ETHYL] 4 MORPHOLINOPYRIDINE; 3 OXO N (5 PHENYLPYRAZINYL) SPIRO (ISOBENZOFURAN 1(3H), 4' PIPERIDINE) 1' CARBOXAMIDE; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y1 RECEPTOR ANTAGONIST; NEUROPEPTIDE Y5 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FAT INTAKE; FEEDING BEHAVIOR; HOMEOSTASIS; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; SINGLE DRUG DOSE; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; BODY WEIGHT; DIETARY FATS; DRUG SYNERGISM; EATING; ENERGY METABOLISM; HOMEOSTASIS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MORPHOLINES; OBESITY; PYRIDINES; RECEPTORS, NEUROPEPTIDE Y; SPIRO COMPOUNDS; THIAZOLES;

EID: 67449116294     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.05.018     Document Type: Article

References (32)

1. Batterham R.L., Cowley M.A., Small C.J., Herzog H., Cohen M.A., Dakin C.L., Wren A.M., Brynes A.E., Low M.J., Ghatei M.A., Cone R.D., and Bloom S.R. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418 (2002) 650-654
2. Djellas Y., Antonakis K., and Le Breton G.C. Shifts in the affinity distribution of one class of seven-transmembrane receptors by activation of a separate class of seven-transmembrane receptors. Biochem. Pharmacol. 59 (2000) 1521-1529
3. Erondu N., Gantz I., Musser B., Suryawanshi S., Mallick M., Addy C., Cote J., Bray G., Fujioka K., Bays H., Hollander P., Sanabria-Bohorquez S.M., Eng W., Langstrom B., Hargreaves R.J., Burns H.D., Kanatani A., Fukami T., Macneil D.J., Gottesdiener K.M., Amatruda J.M., Kaufman K.D., and Heymsfield S.B. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell. Metab. 4 (2006) 275-282
4. Fetissov S.O., Kopp J., and Hokfelt T. Distribution of NPY receptors in the hypothalamus. Neuropeptides 38 (2004) 175-188
5. Gehlert D.R., Schober D.A., Morin M., and Berglund M.M. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties. Biochem. Pharmacol. (2007)
6. George S.R., Fan T., Xie Z., Tse R., Tam V., Varghese G., and O'Dowd B.F. Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J. Biol. Chem. 275 (2000) 26128-26135
7. Gerald C., Walker M.W., Criscione L., Gustafson E.L., Batzl-Hartmann C., Smith K.E., Vaysse P., Durkin M.M., Laz T.M., Linemeyer D.L., Schaffhauser A.O., Whitebread S., Hofbauer K.G., Taber R.I., Branchek T.A., and Weinshank R.L. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 382 (1996) 168-171
8. Gomes I., Gupta A., Filipovska J., Szeto H.H., Pintar J.E., and Devi L.A. A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 5135-5139
9. Gomes I., Jordan B.A., Gupta A., Trapaidze N., Nagy V., and Devi L.A. Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. J. Neurosci. 20 (2000) RC110
10. Halford J.C. Pharmacotherapy for obesity. Appetite 46 (2006) 6-10
11. Hansen J.L., and Sheikh S.P. Functional consequences of 7TM receptor dimerization. Eur. J. Pharm. Sci. 23 (2004) 301-317
12. Holtback U., Brismar H., DiBona G.F., Fu M., Greengard P., and Aperia A. Receptor recruitment: a mechanism for interactions between G protein-coupled receptors. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 7271-7275
13. Ishihara A., Kanatani A., Mashiko S., Tanaka T., Hidaka M., Gomori A., Iwaasa H., Murai N., Egashira S., Murai T., Mitobe Y., Matsushita H., Okamoto O., Sato N., Jitsuoka M., Fukuroda T., Ohe T., Guan X., MacNeil D.J., Van der Ploeg L.H., Nishikibe M., Ishii Y., Ihara M., and Fukami T. A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7154-7158
14. James W.P., Astrup A., Finer N., Hilsted J., Kopelman P., Rossner S., Saris W.H., and Van Gaal L.F. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine trial of obesity reduction and maintenance. Lancet 356 (2000) 2119-2125
15. 1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814. Mol. Pharmacol. 59 (2001) 501-505
16. 1 receptor antagonist, 1229U91: blockade of neuropeptide Y-induced and physiological food intake. Endocrinology 137 (1996) 3177-3182
17. 5 receptor antagonist. Biochem. Biophys. Res. Commun. 272 (2000) 169-173
18. 1 receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. Biochem. Biophys. Res. Commun. 266 (1999) 88-91
19. 5 receptor-deficient mice. Endocrinology 141 (2000) 1011-1016
20. Kos, K., Baker, A.R., Jernas, M., Harte, A.L., Clapham, J.C., O'Hare, J.P., Carlsson, L., Kumar, S., McTernan, P.G., 2009. DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue. Diabetes Obes Metab. 11, 285-292.
21. 5 neuropeptide Y receptor in feeding and obesity. Nat. Med. 4 (1998) 718-721
22. 5 antagonist in obese mice: combination with food restriction or sibutramine. Obesity.(Silver.Spring) 16 (2008) 1510-1515
23. Moriya, R., Mashiko, S., Ishihara, A., Takahashi, T., Murai, T., Ito, J., Mitobe, Y., Oda, Z., Iwaasa, H., Takehiro, F., Kanatani, A., in press. Comparison of independent and combined chronic anti-obese effects of NPY Y2 receptor agonist, PYY(3-36), and NPY Y5 receptor antagonist in diet-induced obese mice. Peptides. doi:10.1016/j.peptides.2009.04.006.
24. 1 receptor agonists with orexigenic activity in vivo. Mol. Pharmacol. 60 (2001) 534-540
25. Parker E., Van Heek M., and Stamford A. Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status. Eur. J. Pharmacol. 440 (2002) 173-187
26. 1 receptor. Nat. Med. 4 (1998) 722-726
27. Prinster S.C., Hague C., and Hall R.A. Heterodimerization of g protein-coupled receptors: specificity and functional significance. Pharmacol. Rev. 57 (2005) 289-298
28. Sjostrom L., Rissanen A., Andersen T., Boldrin M., Golay A., Koppeschaar H.P., and Krempf M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 352 (1998) 167-172
29. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., and Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
30. 1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br. J. Pharmacol. 125 (1998) 549-555
31. 5 receptors in the rat brain by using immunohistochemistry. J. Comp. Neurol. 464 (2003) 285-311
32. Yang K., Guan H., Arany E., Hill D.J., and Cao X. Neuropeptide Y is produced in visceral adipose tissue and promotes proliferation of adipocyte precursor cells via the Y1 receptor. FASEB. J. 7 (2008) 2452-2464